I feel like the only way cu64-Sartate is able to be commercialised before cu64-BCR or Pre prostatectomy is through an accelerated approval pathway. Cu64 wasn’t even in the picture for me as it seemed like the longer pathway to commercialisation.
Interesting points not mentioned here: AT spoke about delaying the dose expansion for a new IND for the new formulation. This will create a slight delay, but i assume that the new patent means a longer period for exclusitivity.
The other is the discussion around potentially partnering the antibody-cu67 therapy with a company that is more experienced in antibody development. I wonder what the chances are of a securing a partnership this year for their antibody combo.
- Forums
- ASX - By Stock
- CU6 - Media and Industry News
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
0.00%
!
$4.33

I feel like the only way cu64-Sartate is able to be...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.33 |
Change
0.000(0.00%) |
Mkt cap ! $1.400B |
Open | High | Low | Value | Volume |
$4.31 | $4.44 | $4.20 | $11.74M | 2.723M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | $4.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.34 | 132 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5623 | 4.670 |
2 | 381 | 4.380 |
1 | 1500 | 4.350 |
1 | 420 | 4.340 |
3 | 2846 | 4.330 |
Price($) | Vol. | No. |
---|---|---|
4.120 | 2920 | 1 |
4.250 | 99 | 1 |
4.330 | 1529 | 2 |
4.340 | 132 | 1 |
4.370 | 1 | 1 |
Last trade - 16.16pm 30/07/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |